Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Arcus Biosciences, Inc.NYSE: RCUS
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow dips below year-ago levels
Q2 FY2026 financing cash flow of $16M fell 69.2% year over year, behind the +30.4% change in trailing-twelve-month financing cash flow. Sequentially, it rose 433.3% from the prior quarter. Over 3 fiscal years it compounded at +145.5% a year.
Context
- Financing cash flow amounted to 197.6% of revenue in FY2025, up 90.2 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -69.2% toward the trailing-twelve-month pace of +30.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 488M USD
- Year-over-year change
- +76.2%
- 4-year CAGR
- +19.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 488M | +76.2% |
| FY2024 | 2024-12-31 | 277M | +739.4% |
| FY2023 | 2023-12-31 | 33M | +0.0% |
| FY2022 | 2022-12-31 | 33M | -86.1% |
| FY2021 | 2021-12-31 | 237.34M | — |
Financing Cash Flow vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 financing cash flow of $313M is the 6th largest of the 9 companies compared; the peer median is $400.84M.
- Its year-over-year change of +30.4% is the 5th highest of 9, against a peer median of +73.6%.
- Financing cash flow amounts to 267.5% of revenue for RCUS, versus a peer median of 206.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $861.53M | +1082.7% | +75.1% | — | |
| LTM Jun 2026 | $748.24M | +157.6% | +9.8% | 1052.0% | |
| LTM Mar 2026 | $557.83M | +3601.6% | +628.3% | 1072.0% | |
| LTM Jun 2026 | $425.38M | +1810.7% | -15.2% | 11803.1% | |
| LTM Sep 2026 | $376.3M | -16.8% | +19.7% | 206.1% | |
| LTM Jun 2026 | $313M | +30.4% | +145.5% | 267.5% | |
| LTM Jun 2026 | $107.69M | -77.5% | +62.4% | 69.0% | |
| LTM Jun 2026 | $40.85M | -75.7% | -2.8% | 9.1% | |
| LTM Mar 2026 | $9.14M | -10.4% | +54.6% | 13.8% | |
| Peer median (excluding RCUS) | $400.84M | +73.6% | +37.1% | 206.1% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 52.83M | (267M) | (307M) | (283M) | (353M) |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 55M | 65M | 73M | 76M | 60M |
| Change in Working Capital | (375.62M) | 623M | (71M) | 22M | (194M) |
| Accounts Receivables | (17.05M) | 704M | 15M | 28M | 9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.77M) | 8M | (1M) | 3M | 24M |
| Other Working Capital | (353.8M) | (89M) | (85M) | (9M) | (227M) |
| Other Non-Cash Items | 7.62M | 11M | (9M) | 5M | (5M) |
| Operating Cash Flow | (256.17M) | 438M | (306M) | (170M) | (482M) |
| Capital Expenditures | (26.08M) | (6M) | (24M) | (6M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (718.87M) | (1.24B) | (788M) | (1.04B) | (1.08B) |
| Sales of Investments | 741.08M | 837M | 1.01B | 965M | 1.14B |
| Other Investing Activities | 0 | (3M) | 0 | 0 | 0 |
| Investing Cash Flow | (3.87M) | (413M) | 194M | (84M) | 66M |
| Debt Repayment | 5M | 0 | 0 | 47M | 49M |
| Common Stock Issued | 232.35M | 23M | 25M | 228M | 439M |
| Common Stock Repurchased | (6K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 10M | 8M | 2M | 0 |
| Financing Cash Flow | 237.34M | 33M | 33M | 277M | 488M |
| Effect of Forex Changes | (2.8M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | (25.5M) | 58M | (79M) | 23M | 72M |
| Free Cash Flow | (282.25M) | 432M | (330M) | (176M) | (484M) |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.